Effectiveness over time of varicella vaccine
- PMID: 14970064
- DOI: 10.1001/jama.291.7.851
Effectiveness over time of varicella vaccine
Abstract
Context: Reports of outbreaks of varicella in highly immunized groups have increased concern about the effectiveness of varicella vaccine.
Objective: To assess whether the effectiveness of varicella vaccine is affected either by time since vaccination or by age at the time of vaccination.
Design: Case-control study conducted from March 1997 through June 2003.
Setting: Twenty different group practices in southern Connecticut.
Participants: Case subjects, identified by active surveillance of all practices, consisted of 339 eligible children 13 months or older who were clinically diagnosed as having chickenpox and who also had a polymerase chain reaction (PCR) test result that was positive for varicella-zoster virus DNA. For each case subject, 2 controls were selected, matched by both age and pediatric practice.
Main outcome measures: The effectiveness of the vaccine, especially the effects of time since vaccination and age at the time of vaccination, adjusted for possible confounders.
Results: Although the adjusted overall effectiveness of the vaccine was 87% (95% confidence interval, 81%-91%; P<.001), there was a substantial difference in the vaccine's effectiveness in the first year after vaccination (97%) and in years 2 to 8 after vaccination (84%, P =.003). The vaccine's effectiveness in year 1 was substantially lower if the vaccine was administered at younger than 15 months (73%) than if it was administered at 15 months or older (99%, P =.01), although the difference in effectiveness overall for children immunized at younger than 15 months was not statistically significantly different than for those immunized at 15 months or older (81% vs 88%, P =.17). Most cases of chickenpox in vaccinees were mild.
Conclusions: Although varicella vaccine is effective, its effectiveness decreases significantly after 1 year, although most cases of breakthrough disease are mild. If administered at younger than 15 months, the vaccine's effectiveness was lower in the first year after vaccination, but the difference in effectiveness was not statistically significant for subsequent years.
Comment in
-
Effectiveness over time of varicella vaccine.J Pediatr. 2004 Sep;145(3):416-7. doi: 10.1016/j.jpeds.2004.06.035. J Pediatr. 2004. PMID: 15343204 No abstract available.
Similar articles
-
The effectiveness of the varicella vaccine in clinical practice.N Engl J Med. 2001 Mar 29;344(13):955-60. doi: 10.1056/NEJM200103293441302. N Engl J Med. 2001. PMID: 11274621
-
One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?Pediatrics. 2006 Jun;117(6):e1070-7. doi: 10.1542/peds.2005-2085. Pediatrics. 2006. PMID: 16740809
-
The effectiveness of varicella vaccination in children in Germany: a case-control study.Pediatr Infect Dis J. 2013 Sep;32(9):998-1004. doi: 10.1097/INF.0b013e31829ae263. Pediatr Infect Dis J. 2013. PMID: 23694831 Clinical Trial.
-
Varicella vaccination of children in the United States: assessment after the first decade 1995-2005.J Clin Virol. 2005 Jun;33(2):89-95; discussion 96-8. doi: 10.1016/j.jcv.2005.02.003. J Clin Virol. 2005. PMID: 15911422 Review.
-
Varicella zoster virus infections in children after the introduction of live attenuated varicella vaccine.Curr Opin Pediatr. 2004 Feb;16(1):80-4. doi: 10.1097/00008480-200402000-00015. Curr Opin Pediatr. 2004. PMID: 14758119 Review.
Cited by
-
Computational design of prefusion-stabilized Herpesvirus gB trimers.bioRxiv [Preprint]. 2024 Oct 24:2024.10.23.619923. doi: 10.1101/2024.10.23.619923. bioRxiv. 2024. PMID: 39484573 Free PMC article. Preprint.
-
An analysis of risk factors for visceral disseminated varicella in children.Front Pediatr. 2024 May 30;12:1345272. doi: 10.3389/fped.2024.1345272. eCollection 2024. Front Pediatr. 2024. PMID: 38873587 Free PMC article.
-
Live-attenuated virus vaccine defective in RNAi suppression induces rapid protection in neonatal and adult mice lacking mature B and T cells.Proc Natl Acad Sci U S A. 2024 Apr 23;121(17):e2321170121. doi: 10.1073/pnas.2321170121. Epub 2024 Apr 17. Proc Natl Acad Sci U S A. 2024. PMID: 38630724 Free PMC article.
-
Varicella Vaccine: a Molecular Variant That May Contribute to Attenuation.mBio. 2022 Dec 20;13(6):e0312022. doi: 10.1128/mbio.03120-22. Epub 2022 Dec 5. mBio. 2022. PMID: 36468883 Free PMC article.
-
Global varicella vaccination programs.Clin Exp Pediatr. 2022 Dec;65(12):555-562. doi: 10.3345/cep.2021.01564. Epub 2022 Nov 2. Clin Exp Pediatr. 2022. PMID: 36457198 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
